{"id":41207,"date":"2025-10-23T17:24:38","date_gmt":"2025-10-23T15:24:38","guid":{"rendered":"https:\/\/purama.lt\/?p=41207"},"modified":"2025-10-30T11:54:01","modified_gmt":"2025-10-30T09:54:01","slug":"sirds-veseliba-nav-tikai-slikts-holesterina-limenis","status":"publish","type":"post","link":"https:\/\/purama.lt\/lv\/sirdies-sveikata-ne-tik-blogasis-cholesterolis\/","title":{"rendered":"Sirds vesel\u012bba: ne tikai sliktais holester\u012bns"},"content":{"rendered":"

Ilgm\u016b\u017e\u012bba un sirds vesel\u012bba: k\u0101p\u0113c nepietiek tikai ar slikto holester\u012bnu?<\/strong><\/h2>\n\n\n\n

Sirds un asinsvadu slim\u012bbu risku nosaka ne tikai ZBL l\u012bmenis. Svar\u012bgi ir redz\u0113t visu kopainu: cik daudz aterog\u0113no da\u013ci\u0146u cirkul\u0113 asin\u012bs (ApoB), hronisku iekaisuma fonu (hsCRP) un endot\u0113lija - asinsvadu iek\u0161\u0113j\u0101 sl\u0101\u0146a - st\u0101vokli. Ja ir liels da\u013ci\u0146u skaits un iekaisums, pl\u0101ksn\u012btes m\u0113dz b\u016bt akt\u012bv\u0101kas un nestabil\u0101kas, pat ja ZBL-C \u201edokumenti\u201c izskat\u0101s labi.<\/p>\n\n\n\n

ApoB ir praktisks da\u013ci\u0146u skaita r\u0101d\u012bt\u0101js. Diviem cilv\u0113kiem var b\u016bt l\u012bdz\u012bgs ZBL-C, bet cilv\u0113kam ar augst\u0101ku ApoB ir liel\u0101ka iesp\u0113jam\u012bba, ka tas ir pak\u013cauts liel\u0101kam riskam, jo vair\u0101k da\u013ci\u0146u noz\u012bm\u0113 liel\u0101ku kontaktu ar asinsvadu sieni\u0146\u0101m. hsCRP nav specifisks r\u0101d\u012bt\u0101js, bet tas pal\u012bdz saprast, vai organism\u0101 ir zemas pak\u0101pes iekaisums, kas veicina pl\u0101ksn\u012b\u0161u darb\u012bbu. Lp(a) ir \u0123en\u0113tiski noteikts faktors; ir v\u0113rts to p\u0101rbaud\u012bt vismaz vienu reizi un, ja tas ir augsts, stingr\u0101k kontrol\u0113t citus riska komponentus. CAC sken\u0113\u0161ana pal\u012bdz nov\u0113rt\u0113t patieso boj\u0101juma slogu, \u012bpa\u0161i tad, ja kop\u0113jais risks ir m\u0113rens un ir nolemts lietot medikamentus.<\/p>\n\n\n\n

Praks\u0113 tas noz\u012bm\u0113 divus paral\u0113lus m\u0113r\u0137us: da\u013ci\u0146u skaita samazin\u0101\u0161anu un iekaisuma fona apspie\u0161anu. Pirmajam m\u0113r\u0137im bie\u017ei vien pietiek ar di\u0113tas un svara korekcij\u0101m, k\u0101 ar\u012b \u0101rsta noz\u012bm\u0113tiem medikamentiem (stat\u012bni, ezetimibs, PCSK9 u. c.), ja tie ir indic\u0113ti. Otrajam m\u0113r\u0137im visliel\u0101ko efektu sniedz Vidusj\u016bras tipa di\u0113ta, regul\u0101ra aerobika un sp\u0113ka treni\u0146u lieto\u0161ana, kvalitat\u012bvs miegs un glik\u0113mijas stabilit\u0101te. Endot\u0113lija funkciju uzlabo tie pa\u0161i faktori: asinsspiediena kontrole, cukura l\u012bme\u0146a sv\u0101rst\u012bbu mazin\u0101\u0161ana, sm\u0113\u0137\u0113\u0161anas atme\u0161ana.<\/p>\n\n\n\n

Papildin\u0101jumi var pal\u012bdz\u0113t, bet tie ir tikai papildin\u0101jums. Omega-3 (EPA+DHA) labv\u0113l\u012bgi ietekm\u0113 triglicer\u012bdu veido\u0161anos un pl\u0101ksn\u012b\u0161u stabilit\u0101ti, \u0161\u0137\u012bsto\u0161\u0101s \u0161\u0137iedrvielas veicina ZBL samazin\u0101\u0161anos, kurkum\u012bna ekstrakts - iekaisuma fona uzlabo\u0161anos. Devas un kombin\u0101cija ar medikamentiem j\u0101apsprie\u017e ar \u0101rstu.<\/p>\n\n\n\n

Vislab\u0101k ir str\u0101d\u0101t cikliski. Nosakiet s\u0101kotn\u0113jo st\u0101vokli (ApoB, ZBL-C, hsCRP; Lp(a), CAC, ja nepiecie\u0161ams), \u012bstenojiet pl\u0101nu 8-12 ned\u0113\u013cas un atk\u0101rtojiet test\u0113\u0161anu. Ja progress ir l\u0113ns, kori\u0123\u0113jiet di\u0113tu, fizisk\u0101s aktivit\u0101tes vai terapiju. \u0160\u012b pieeja samazina aterog\u0113no da\u013ci\u0146u pl\u016bsmu, p\u0101rvarot iekaisumu un stiprinot endot\u0113liju, kas ir dro\u0161\u0101kais ce\u013c\u0161 uz maz\u0101ku ak\u016btu notikumu risku.<\/p>\n\n\n\n

\n\n\n\n

Kas \u012bsti notiek asinsvad\u0101?<\/strong><\/h3>\n\n\n\n

Ja endot\u0113lija sieni\u0146a ir boj\u0101ta (augsts asinsspiediens, glik\u0113mijas sv\u0101rst\u012bbas, sm\u0113\u0137\u0113\u0161ana, oksidat\u012bvais stress), ZBL da\u013ci\u0146as<\/strong> viegl\u0101k iek\u013c\u016bst sien\u0101. Tur tie tiek \u201eapstr\u0101d\u0101ti\u201c im\u016bn\u0101s \u0161\u016bnas - makrof\u0101gi<\/strong>. Ja ZBL da\u013ci\u0146u ir daudz, t\u0101s vair\u0101k oksid\u0113jas, makrof\u0101gi \u201eiestr\u0113gst\u201c, veidojot tukl\u0101s \u0161\u016bnas<\/strong>, kas baro hronisks iekaisums<\/strong>. Tas sabiezina aterosklerotisko pl\u0101ksn\u012bti un palielina t\u0101s nestabilit\u0101te<\/strong> risks (pl\u012bsums \u2192 trombs \u2192 sirdsl\u0113kme\/insults).<\/p>\n\n\n\n

Secin\u0101jums:<\/strong> svar\u012bgi aterog\u0113no da\u013ci\u0146u (ApoB\/LDL-C) skaita samazin\u0101\u0161ana.<\/strong> un nomierina iekaisumu (hsCRP, dz\u012bvesveids).<\/strong>.<\/p>\n\n\n\n

\n\n\n\n

K\u0101p\u0113c nepietiek tikai ar ZBL-C?<\/strong><\/h3>\n\n\n\n

ZBL-C<\/strong> (ZBL holester\u012bns) joproj\u0101m ir b\u0101zes r\u0101d\u012bt\u0101js, bet:<\/p>\n\n\n\n

    \n
  • Vi\u0146\u0161 ne vienm\u0113r<\/strong> prec\u012bzi atspogu\u013co da\u013ci\u0146u skaits<\/strong>. \u0160aj\u0101 gad\u012bjum\u0101 valoda ir prec\u012bz\u0101ka ApoB<\/strong> - cik \u201evagonu\u201c ierad\u0101s, nevis cik daudz \u201ekravas\u201c.<\/li>\n\n\n\n
  • Diviem cilv\u0113kiem ar vien\u0101du ZBL-C, no kuriem viens ir ar ApoB<\/strong> augst\u0101ks, var b\u016bt augst\u0101ks risks<\/strong>.<\/li>\n\n\n\n
  • hsCRP<\/strong> Atkl\u0101j iekaisuma fons<\/strong> - ja tas ir augsts, pl\u0101ksn\u012btes paliek akt\u012bv\u0101ka un nestabil\u0101ka<\/strong>, pat p\u0113c ZBL \u201ekorekcijas\u201c.<\/li>\n<\/ul>\n\n\n\n

    Praktiskais riska panelis:<\/strong><\/p>\n\n\n\n

      \n
    • ApoB<\/strong> - M\u0113r\u0137is ir samazin\u0101t aterog\u0113no da\u013ci\u0146u skaitu.<\/li>\n\n\n\n
    • ZBL-C<\/strong> - pamatl\u012bnija, parasti pirmais m\u0113r\u0137is.<\/li>\n\n\n\n
    • hsCRP<\/strong> - pal\u012bdz saskat\u012bt iekaiso\u0161o toni.<\/li>\n\n\n\n
    • Lp(a)<\/strong> - \u0123en\u0113tiski noteikts; vismaz vienreiz m\u016b\u017e\u0101<\/strong> v\u0113rts zin\u0101t.<\/li>\n\n\n\n
    • CAC<\/strong> (koron\u0101ro art\u0113riju kalcifik\u0101cijas sken\u0113\u0161ana) - noder\u012bga, ja risks Vid\u0113ja<\/strong> un l\u0113mumu pie\u0146em\u0161ana par medikamentiem; par\u0101dot re\u0101li<\/strong> pl\u0101k\u0161\u0146u slogs.<\/li>\n<\/ul>\n\n\n\n

      Zin\u0101tne akt\u012bvi p\u0113ta virzienus, kas izl\u012bdzina im\u016bnsist\u0113mas reakciju.<\/strong> un ir v\u0113rsta uz pl\u0101ksnes mikrovidi:<\/p>\n\n\n\n

        \n
      • Cito\u0137\u012bmiskie m\u0113r\u0137i<\/strong> (piem., IL-1\u03b2, IL-6) - konceptu\u0101lais m\u0113r\u0137is ir mazin\u0101t aizdedzes dzin\u0113js<\/strong> da\u017e\u0101s pacientu apak\u0161grup\u0101s.<\/li>\n\n\n\n
      • Makrof\u0101gu polariz\u0101cija<\/strong> - v\u0113lme \u201ep\u0101rkvalific\u0113t\u201c makrof\u0101gus uz remonts<\/strong> statuss.<\/li>\n\n\n\n
      • CHIP<\/strong> (klonu mut\u0101cijas hematopo\u0113tiskaj\u0101s \u0161\u016bn\u0101s ar vecumu) - var izrais\u012bt iekaisuma fons<\/strong>, izskaidro, k\u0101p\u0113c risks pieaug vec\u0101k\u0101 vecum\u0101, pat ja tiek nodro\u0161in\u0101ta lip\u012bdu kontrole.<\/li>\n\n\n\n
      • M\u0113r\u0137tiec\u012bga pieg\u0101de<\/strong> (piem\u0113ram, nanoda\u013ci\u0146as) - lai z\u0101les darbotos. pl\u0101ksne<\/strong>, ne visu \u0137ermeni.<\/li>\n<\/ul>\n\n\n\n

        Svar\u012bgi:<\/strong> daudzi - kl\u012bniskie p\u0113t\u012bjumi<\/strong>, t\u0101 nav \u201evien\u0101da visiem \u0161odien\u201c.<\/p>\n\n\n\n

        \n\n\n\n

        Ko varat dar\u012bt tagad: 4 so\u013cu strat\u0113\u0123ija<\/strong><\/h3>\n\n\n\n

        1) Papla\u0161in\u0101tais nov\u0113rt\u0113jums (nevis viens skaitlis)<\/strong><\/p>\n\n\n\n

        Ir v\u0113rts apspriesties ar savu \u0101rstu:<\/p>\n\n\n\n

          \n
        • ApoB<\/strong> \u2714\ufe0f Prec\u012bz\u0101ks nek\u0101 ZBL-C, jo par\u0101da da\u013ci\u0146as. skait\u013ci<\/strong>.<\/li>\n\n\n\n
        • ZBL-C<\/strong> \u2714\ufe0f Galvenais \u201eslikt\u0101 holester\u012bna\u201c r\u0101d\u012bt\u0101js.<\/li>\n\n\n\n
        • hsCRP<\/strong> \u2714\ufe0f Augstas jut\u012bbas C-reakt\u012bvais prote\u012bns - iekaisums<\/strong> r\u0101d\u012bt\u0101js.<\/li>\n\n\n\n
        • Lp(a)<\/strong> \u2714\ufe0f \u0122en\u0113tiskais faktors, lietder\u012bgi zin\u0101t vismaz vienreiz<\/strong>.<\/li>\n\n\n\n
        • CAC<\/strong> \u2714\ufe0f \u012apa\u0161i, ja atrodaties \u201epel\u0113kaj\u0101 zon\u0101\u201c - pal\u012bdz jums pie\u0146emt l\u0113mumu par z\u0101l\u0113m.<\/li>\n<\/ul>\n\n\n\n

          M\u0113r\u0137is:<\/strong> vienojieties ar savu \u0101rstu par s\u0101kotn\u0113jais m\u0113r\u0137is<\/strong> (piem\u0113ram, ZBL-C < 2,6 mmol\/l vai stingr\u0101ki m\u0113r\u0137i riska gad\u012bjumiem); un kontroles pl\u0101ns<\/strong> (zem\u0101k).<\/p>\n\n\n\n

          \n\n\n\n

          2) Dz\u012bvesveids - j\u016bsu dabiskais im\u016bnmodulators<\/strong><\/p>\n\n\n\n

          Uzturs (Vidusj\u016bras modelis):<\/strong><\/p>\n\n\n\n

            \n
          • Ol\u012bve\u013c\u013ca, d\u0101rze\u0146i, p\u0101k\u0161augi, pilngraudu produkti, rieksti, s\u0113klas, zivis.<\/li>\n\n\n\n
          • Maz\u0101k p\u0101rstr\u0101d\u0101tu, rafin\u0113tu cukuru, transtauksk\u0101bju, p\u0101rm\u0113r\u012bga alkohola daudzuma.<\/li>\n<\/ul>\n\n\n\n

            K\u0101p\u0113c:<\/strong>
            \u2714\ufe0f Uzlabo lip\u012bdu profilu (ZBL-C\/ApoB).
            \u2714\ufe0f Samazina sist\u0113misko iekaisumu (hsCRP).
            \u2714\ufe0f Nostiprina zarnu mikrobiotu (metabol\u012btu l\u012bdzsvaru).<\/p>\n\n\n\n

            Kust\u012bba:<\/strong><\/p>\n\n\n\n

              \n
            • 150-300 min.\/sav.<\/strong> aerobika + 2 reizes\/sav.<\/strong> sp\u0113ka vingrin\u0101jumi.<\/li>\n\n\n\n
            • Ikdienas NEAT (so\u013ci, k\u0101pnes, darbs st\u0101vus) - \u201eneredzamais\u201c kaloriju dedzin\u0101t\u0101js.<\/li>\n<\/ul>\n\n\n\n

              K\u0101p\u0113c:<\/strong>
              \u2714\ufe0f Samazina insul\u012bna rezistenci un glik\u0113mijas sv\u0101rst\u012bbas.
              \u2714\ufe0f Uzlabo endot\u0113lija funkciju un NO (sl\u0101pek\u013ca oks\u012bda) biolo\u0123isko daudzveid\u012bbu.
              \u2714\ufe0f Nov\u0113r\u0161 iekaisumu, uzlabo garast\u0101vokli un miegu.<\/p>\n\n\n\n

              Svara kontrole:<\/strong><\/p>\n\n\n\n

                \n
              • Ja \u0136MI > 25<\/strong>, mekl\u0113t -5-10 %<\/strong> \u0137erme\u0146a masa.<\/li>\n\n\n\n
              • Liel\u0101ks ieguvums viduk\u013ca apk\u0101rtm\u0113ra (viscer\u0101lo tauku) samazin\u0101\u0161an\u0101.<\/li>\n<\/ul>\n\n\n\n

                K\u0101p\u0113c:<\/strong>
                \u2714\ufe0f Iev\u0113rojami samazina sist\u0113misko iekaisumu.
                \u2714\ufe0f Uzlabo lip\u012bdu un asinsspiedienu.<\/p>\n\n\n\n

                Miegs un stress:<\/strong><\/p>\n\n\n\n

                  \n
                • no plkst. 7 l\u012bdz 9 r\u012bt\u0101.<\/strong> miegs, regul\u0101rs ritms.<\/li>\n\n\n\n
                • Elpo\u0161anas vingrin\u0101jumi, \u012bsas pastaigas, ierobe\u017eots ekr\u0101na laiks vakar\u0101.<\/li>\n<\/ul>\n\n\n\n

                  K\u0101p\u0113c:<\/strong>
                  \u2714\ufe0f Balans\u0113\u0161ana kortizola<\/strong> un iekaisuma<\/strong> sign\u0101li.
                  \u2714\ufe0f Pal\u012bdz kontrol\u0113t apet\u012bti un glik\u0113miju.<\/p>\n\n\n\n

                  3) Papildu vielas: piesardz\u012bgi, m\u0113r\u0137tiec\u012bgi, p\u0113c \u0101rsta ieteikuma<\/strong><\/p>\n\n\n\n

                  Piez\u012bme:<\/strong> Papildin\u0101jumi nevar aizst\u0101t<\/strong> \u0101rsta izrakst\u012btas z\u0101les un ne\u0101rst\u0113<\/strong> slim\u012bbas; t\u0101s var Skat\u012bt vair\u0101k<\/strong> di\u0113tas un dz\u012bvesveida izmai\u0146as. \u012apa\u0161i, ja lietojat medikamentus (piem\u0113ram, antikoagulantus), pirms uztura bag\u0101tin\u0101t\u0101ju lieto\u0161anas. konsult\u0113jieties ar .<\/strong> ar savu \u0101rstu.<\/p>\n\n\n\n

                  a) EPA\/DHA (zivju e\u013c\u013ca, omega-3)<\/strong><\/p>\n\n\n\n

                  M\u0113r\u0137is:<\/strong> triglicer\u012bdu samazin\u0101\u0161an\u0101s, iekaisuma tonusa l\u012bdzsvars, iesp\u0113jama pl\u0101ksn\u012b\u0161u stabilit\u0101te.
                  K\u0101 izv\u0113l\u0113ties:<\/strong> koncentr\u0113t\u0101 veid\u0101, skaidri nor\u0101d\u012bts EPA + DHA mg<\/strong> uz vienu porciju dien\u0101.
                  Lieto\u0161anas vadl\u012bnijas:<\/strong> bie\u017eas dienas devas ~ 1000-2000 mg EPA+DHA<\/strong> (individu\u0101li).
                  K\u0101p\u0113c:<\/strong>
                  \u2714\ufe0f Pal\u012bdz samazin\u0101t triglicer\u012bdu l\u012bmeni.
                  \u2714\ufe0f Var saglab\u0101t endot\u0113lija un pl\u0101ksnes stabilit\u0101ti.
                  \u2714\ufe0f Apvienojum\u0101 ar Vidusj\u016bras di\u0113tu (2-3 gab.\/s\u0113klu).<\/p>\n\n\n\n

                  (b) \u0161\u0137\u012bsto\u0161\u0101s \u0161\u0137iedrvielas (psilijs, auzu beta-glik\u0101ni).<\/strong><\/p>\n\n\n\n

                  M\u0113r\u0137is:<\/strong> samazina holester\u012bna uzs\u016bk\u0161anos, zarnu vesel\u012bbu.
                  Lieto\u0161anas vadl\u012bnijas:<\/strong> bie\u017ei 5-10 g\/d.<\/strong> \u0161\u0137\u012bsto\u0161\u0101s \u0161\u0137iedrvielas (porcij\u0101s, ar \u0161\u0137idrumu).
                  K\u0101p\u0113c:<\/strong>
                  \u2714\ufe0f Pal\u012bdz samazin\u0101t ZBL-C<\/strong>.
                  \u2714\ufe0f S\u0101ta saj\u016bta, \u201eglik\u0113mijas l\u012bknes izl\u012bdzin\u0101\u0161ana\u201c.
                  \u2714\ufe0f Mikrobi\u0101las izcelsmes \u012bsas \u0137\u0113des tauksk\u0101bes - pretiekaisuma l\u012bdzeklis<\/strong> ietekme.<\/p>\n\n\n\n

                  (c) augu ster\u012bni\/stanoli<\/strong><\/p>\n\n\n\n

                  M\u0113r\u0137is:<\/strong> konkur\u0113 par holester\u012bna uzs\u016bk\u0161anos zarn\u0101s.
                  Lieto\u0161anas vadl\u012bnijas:<\/strong> Par 1,5-2 g\/d.<\/strong> (no bag\u0101tin\u0101tiem produktiem vai uztura bag\u0101tin\u0101t\u0101jiem).
                  K\u0101p\u0113c:<\/strong>
                  \u2714\ufe0f Samazina ZBL-C<\/strong>.
                  \u2714\ufe0f Piem\u0113rots k\u0101 uzturv\u0113rt\u012bba<\/strong> ZBL \u201ebremz\u0113jas\u201c, kad main\u0101t di\u0113tu.<\/p>\n\n\n\n

                  (d) Bergamotes ekstrakts (Citrus bergamia)<\/strong><\/p>\n\n\n\n

                  M\u0113r\u0137is:<\/strong> lip\u012bdu profils (ZBL, triglicer\u012bdi), antioksidantu potenci\u0101ls.
                  Lieto\u0161anas vadl\u012bnijas:<\/strong> j\u0101iev\u0113ro ra\u017eot\u0101ja nor\u0101d\u012bjumi (standartiz\u0113ts polifenola saturs).
                  K\u0101p\u0113c:<\/strong>
                  \u2714\ufe0f Polifenoli var pal\u012bdz\u0113t lip\u012bdu l\u012bdzsvaram.
                  \u2714\ufe0f Papildu antioksidantu \u201evairogs\u201c ar uzturu.<\/p>\n\n\n\n

                  e) kurkum\u012bns (kurkuma ekstrakts ar piper\u012bnu vai liposom\u0101li)<\/strong><\/p>\n\n\n\n

                  M\u0113r\u0137is:<\/strong> uzliesmojo\u0161s tonuss<\/strong> Vad\u012bba.
                  Lieto\u0161anas vadl\u012bnijas:<\/strong> standartiz\u0113tas formas, lab\u0101ka bioabsorbcijas tehnolo\u0123ija.
                  K\u0101p\u0113c:<\/strong>
                  \u2714\ufe0f Pal\u012bdz samazin\u0101t hsCRP<\/strong> tendences (konteksta ietekme).
                  \u2714\ufe0f Apvienojum\u0101 ar dz\u012bvesveidu, nevis k\u0101 z\u0101\u013cu aizst\u0101j\u0113js.<\/p>\n\n\n\n

                  f) Koenz\u012bms Q10 (\u012bpa\u0161i stat\u012bnu lietot\u0101jiem)<\/strong><\/p>\n\n\n\n

                  M\u0113r\u0137is:<\/strong> mitohondriju ener\u0123iju, musku\u013cu komfortu.
                  Lieto\u0161anas vadl\u012bnijas:<\/strong> 100-200 mg\/d.<\/strong> (individu\u0101li, atkar\u012bb\u0101 no tolerances).
                  K\u0101p\u0113c:<\/strong>
                  \u2714\ufe0f Bie\u017ei izv\u0113las musku\u013cu komfortam<\/strong> stat\u012bni fon\u0101.
                  \u2714\ufe0f Ener\u0123ijas atbalsts akt\u012bvam dz\u012bvesveidam.<\/p>\n\n\n\n

                  Papildin\u0101jumu izv\u0113les \u201emini kontrolsaraksts\u201c:<\/strong>
                  \u2714\ufe0f Clear standartiz\u0113ti materi\u0101li<\/strong> daudzums uz eti\u0137etes.
                  \u2714\ufe0f Tre\u0161\u0101s valstis kvalit\u0101tes testi<\/strong> (smagie met\u0101li, oksid\u0101cija, t\u012br\u012bba).
                  \u2714\ufe0f Doz\u0113\u0161ana<\/strong> saska\u0146\u0101 ar kl\u012bnisko p\u0113t\u012bjumu interv\u0101liem (nevis \u201ehomeop\u0101tisko\u201c).
                  \u2714\ufe0f Savietojam\u012bba<\/strong> ar cit\u0101m z\u0101l\u0113m, ko lietojat (konsult\u0113jieties ar \u0101rstu).<\/p>\n\n\n\n

                  4) Farmaceitisk\u0101 da\u013ca - j\u0101izlemj individu\u0101li ar \u0101rstu.<\/strong><\/p>\n\n\n\n

                    \n
                  • Mucas<\/strong> - parasti ir pirmais solis, ja risks ir palielin\u0101ts.<\/li>\n\n\n\n
                  • Ezetimibs, PCSK9 inhibitori<\/strong> - vajadz\u012bbas gad\u012bjum\u0101 - risku kombin\u0101cijas. ApoB\/LDL<\/strong> v\u0113l vair\u0101k samazin\u0101t.<\/li>\n\n\n\n
                  • Aizdedzes m\u0113r\u0137a blo\u0137\u0113t\u0101ji<\/strong> - \u0161obr\u012bd tikai atlas\u012btiem<\/strong> gad\u012bjumiem un kl\u012bniskaj\u0101<\/strong> situ\u0101cijas.<\/li>\n<\/ul>\n\n\n\n

                    Vad\u012bbas ier\u012bces:<\/strong> atk\u0101rtota nov\u0113rt\u0113\u0161ana p\u0113c 8-12 ned\u0113\u013cas<\/strong> (ApoB\/LDL-C, hsCRP, asinsspiediens, glikoze), tad ik p\u0113c 6-12 m\u0113ne\u0161iem.<\/strong> balst\u012bta uz risku.<\/p>\n\n\n\n

                    \n\n\n\n

                    Ilgm\u016b\u017e\u012bbas praktiz\u0113\u0161ana: ikned\u0113\u013cas pl\u0101na pamats<\/strong><\/h3>\n\n\n\n

                    No pirmdienas l\u012bdz piektdienai<\/strong><\/p>\n\n\n\n

                      \n
                    • Brokastis: grie\u0137u jogurts + ogas + auzas<\/strong> P\u0101rslu + s\u0113klas<\/strong>.<\/li>\n\n\n\n
                    • Pusdienas: sal\u0101ti ar p\u0101k\u0161augi<\/strong>, d\u0101rze\u0146i, ol\u012bve\u013c\u013ca<\/strong>, pilngraudu papildin\u0101jums.<\/li>\n\n\n\n
                    • Vakari\u0146as: zivis<\/strong> 2-3 k.\/\u0113dienu, citreiz liesa m\u0101jputnu ga\u013ca vai tofu, d\u0101rze\u0146i.<\/li>\n\n\n\n
                    • Uzkodas: rieksti<\/strong>, \u0101bolu\/biezeni, \u016bdeni vai t\u0113ju.<\/li>\n\n\n\n
                    • Kust\u012bba: katru dienu pastaigas 30-45 min.<\/strong> + 2<\/strong> Sp\u0113ka treni\u0146\u0161 (45-60 min.)\/pa\u0161i.<\/li>\n\n\n\n
                    • Miegs: no plkst. 7 l\u012bdz 9 r\u012bt\u0101.<\/strong>, stabil\u0101 st\u0101vokl\u012b.<\/li>\n\n\n\n
                    • Stresi: elpo\u0161ana 4-7-8<\/strong> (4 ieelpas, 7 aiztur\u0113jumi, 8 izelpas) - 2-3 cikli.<\/li>\n<\/ul>\n\n\n\n

                      Ned\u0113\u013cas nogale<\/strong><\/p>\n\n\n\n

                        \n
                      • Ilg\u0101ka pastaiga vai p\u0101rg\u0101jiens.<\/li>\n\n\n\n
                      • Soci\u0101l\u0101 saikne bez p\u0101rm\u0113r\u012bga alkohola (iekaisuma fons!).<\/li>\n\n\n\n
                      • P\u0101rtikas sagatavo\u0161ana ned\u0113\u013cai: d\u0101rze\u0146u komplekti, p\u0101k\u0161augu gatavo\u0161ana, zivju porcijas, \u0161\u0137\u012bsto\u0161\u0101s \u0161\u0137iedrvielas<\/strong> Sagatavo\u0161ana.<\/li>\n<\/ul>\n\n\n\n
                        \n\n\n\n

                        Bie\u017e\u0101k pie\u013caut\u0101s k\u013c\u016bdas un k\u0101 no t\u0101m izvair\u012bties<\/strong><\/h3>\n\n\n\n

                        \u201eZBL ir norm\u0101ls - es esmu dro\u0161s.\u201c Ne vienm\u0113r. Nov\u0113rt\u0113jiet ar\u012b ApoB, hsCRP, Lp(a); apsveriet iesp\u0113ju veikt CAC sken\u0113\u0161anu, ja nav skaidrs risks. Tas jums sniegs patieso ainu, nevis vienu skaitli.<\/p>\n\n\n\n

                        \u201ePapildin\u0101jumi aizst\u0101s z\u0101les.\u201c N\u0113. Papildin\u0101jumi ir papildin\u0101jums j\u016bsu di\u0113tai un dz\u012bvesveidam, un par z\u0101\u013cu izrakst\u012b\u0161anu vai mai\u0146u lemj \u0101rsts, \u0146emot v\u0113r\u0101 riskus un r\u0101d\u012bt\u0101jus.<\/p>\n\n\n\n

                        \u201eViens super\u0113diens visu atrisin\u0101s.\u201c Ateroskleroze ir multifaktori\u0101la. Tai nepiecie\u0161ama sist\u0113miska pieeja: di\u0113ta, fizisk\u0101s aktivit\u0101tes, miegs, stresa kontrole un, ja nepiecie\u0161ams, medikamenti.<\/p>\n\n\n\n

                        \u201eEs nesekoju l\u012bdzi r\u0101d\u012bt\u0101jiem, bet es sagaidu progresu.\u201c Bez datiem tas ir tikai min\u0113jums. Izveidojiet b\u0101zes l\u012bniju un pl\u0101nojiet atk\u0101rtotus m\u0113r\u012bjumus p\u0113c 8-12 ned\u0113\u013c\u0101m, lai piel\u0101gotu savu pl\u0101nu faktiem.<\/p>\n\n\n\n

                        \n\n\n\n

                        Uztura bag\u0101tin\u0101t\u0101ju noz\u012bme sirds un asinsvadu riska mazin\u0101\u0161an\u0101<\/strong><\/p>\n\n\n\n

                        Uztura bag\u0101tin\u0101t\u0101ji ir l\u012bdzeklis \u012bpa\u0161iem m\u0113r\u0137iem, lai uzlabotu lip\u012bdu profilu, mazin\u0101tu iekaisuma fonu un uztur\u0113tu endot\u0113lija funkciju. Tie j\u0101izv\u0113las atbilsto\u0161i r\u0101d\u012bt\u0101jiem (ApoB, ZBL-C, triglicer\u012bdi, hsCRP) un j\u0101apvieno ar di\u0113tu, fizisk\u0101m aktivit\u0101t\u0113m un, ja nepiecie\u0161ams, medikamentiem.<\/p>\n\n\n\n

                        1) Lip\u012bdu virziens<\/strong><\/p>\n\n\n\n

                        Omega-3 (EPA+DHA) - koncentr\u0113jas uz triglicer\u012bdu samazin\u0101\u0161anu un pl\u0101ksn\u012b\u0161u stabilit\u0101tes uztur\u0113\u0161anu. Izv\u0113lieties koncentr\u0113tas, uzticamas izcelsmes formas, kur\u0101s skaidri nor\u0101d\u012bts EPA+DHA daudzums dienas porcij\u0101.
                        \u0160\u0137\u012bsto\u0161\u0101s \u0161\u0137iedrvielas (ps\u012blijs, auzu beta-glik\u0101ni) - pal\u012bdz samazin\u0101t ZBL uzs\u016bk\u0161anos zarn\u0101s un uzlabo s\u0101ta saj\u016btu\/glik\u0113mijas kontroli ikdienas uztur\u0101.
                        Augu ster\u012bni\/stanoli - holester\u012bna uzs\u016bk\u0161an\u0101s konkur\u0113tsp\u0113j\u012bga inhib\u012bcija, noder\u012bga, ja ZBL samazin\u0101\u0161an\u0101s tikai ar di\u0113tu ir p\u0101r\u0101k l\u0113na.
                        Bergamotes polifenoli ir papildu risin\u0101jums lip\u012bdu profila l\u012bdzsvaro\u0161anai kombin\u0101cij\u0101 ar racion\u0101lu uzturu.<\/p>\n\n\n\n

                        2) Iekaisuma fons<\/strong><\/p>\n\n\n\n

                        Kurkum\u012bna ekstrakti (uzlabotas biopieejam\u012bbas formas) - ar m\u0113r\u0137i samazin\u0101t zemas pak\u0101pes iekaisuma aktivit\u0101ti (hsCRP konteksts). V\u0113rt\u012bba ir liel\u0101ka, ja uzturs jau ir piel\u0101gots un tiek iev\u0113rots re\u017e\u012bms.<\/p>\n\n\n\n

                        3) Ener\u0123ija un tolerance<\/strong><\/p>\n\n\n\n

                        Koenz\u012bms Q10 - \u0161\u016bnu ener\u0123ijas metabolisma atbalsts; svar\u012bgi saist\u012bb\u0101 ar paaugstin\u0101tu fizisko slodzi vai lip\u012bdu l\u012bmeni pazemino\u0161u terapiju, lai uzlabotu musku\u013cu komfortu.<\/p>\n\n\n\n

                        Integr\u0101cija 8-12 ned\u0113\u013cu pl\u0101n\u0101<\/strong><\/p>\n\n\n\n

                          \n
                        1. S\u0101kotn\u0113jie dati: apoB, ZBL-C, triglicer\u012bdi, hsCRP (Lp(a), ja nepiecie\u0161ams; CAC, ja nav skaidrs risks).<\/li>\n\n\n\n
                        2. Priorit\u0101rais komplekts: piem\u0113ram, omega-3 + \u0161\u0137\u012bsto\u0161\u0101s \u0161\u0137iedrvielas lip\u012bdiem; kurkum\u012bns iekaisuma fona \u0101rst\u0113\u0161anai.<\/li>\n\n\n\n
                        3. \u012asteno\u0161ana: konsekventa lieto\u0161ana kop\u0101 ar di\u0113tu un vingrojumu pl\u0101nu.<\/li>\n\n\n\n
                        4. P\u0113c 8-12 ned\u0113\u013c\u0101m: atk\u0101rtota test\u0113\u0161ana, devas vai prepar\u0101ta piel\u0101go\u0161ana (ja triglicer\u012bdu l\u012bmenis joproj\u0101m ir augsts, palieliniet EPA+DHA; ja ZBL l\u0113ni samazin\u0101s, pievienojiet ster\u012bnus\/stanolus; ja hsCRP saglab\u0101jas stabils, p\u0101rskatiet kurkum\u012bna formu\/dozu un dz\u012bvesveida discipl\u012bnu).<\/li>\n<\/ol>\n\n\n\n

                          Kvalit\u0101tes krit\u0113riji<\/strong>:<\/p>\n\n\n\n

                            \n
                          • Standartiz\u0113ts akt\u012bvo sast\u0101vda\u013cu daudzums un skaidras dienas devas.<\/li>\n\n\n\n
                          • Tre\u0161\u0101s puses kvalit\u0101tes p\u0101rbaudes (t\u012br\u012bba, oksid\u0113\u0161an\u0101s, smagie met\u0101li).<\/li>\n\n\n\n
                          • Devas, kas atbilst piem\u0113rojamos p\u0113t\u012bjumos izmantotaj\u0101m dev\u0101m, nav simboliskas.<\/li>\n\n\n\n
                          • Pirms lieto\u0161anas uzs\u0101k\u0161anas tiek nov\u0113rt\u0113ta sader\u012bba ar eso\u0161aj\u0101m z\u0101l\u0113m.<\/li>\n<\/ul>\n\n\n\n

                            Apak\u0161\u0113j\u0101 l\u012bnija:<\/strong> Uztura bag\u0101tin\u0101t\u0101ji nav pa\u0161m\u0113r\u0137is - tie pal\u012bdz sasniegt noteiktos biomar\u0137ieru m\u0113r\u0137us, ja tiek izv\u0113l\u0113ti, pamatojoties uz datiem, un iek\u013cauti struktur\u0113t\u0101 pl\u0101n\u0101. T\u0101d\u0113j\u0101di tiek pan\u0101kti \u0101tr\u0101ki un notur\u012bg\u0101ki ApoB\/LDL un hsCRP uzlabojumi, vienlaikus saglab\u0101jot labu panesam\u012bbu ikdienas dz\u012bv\u0113.<\/p>\n\n\n\n

                            \n\n\n\n

                            D.U.K.<\/strong><\/h4>\n\n\n\n

                            Vai ar to pietiek, lai \u201esamazin\u0101tu\u201c slikt\u0101 holester\u012bna (ZBL-C) l\u012bmeni?<\/strong>
                            Ne vienm\u0113r. ZBL-C ir svar\u012bgs, bet papildus j\u0101nov\u0113rt\u0113 ar\u012b ApoB<\/strong> (da\u013ci\u0146u skaits) un hsCRP<\/strong> (iekaisums). Da\u017eos gad\u012bjumos var b\u016bt noder\u012bgi Lp(a)<\/strong> un CAC<\/strong>.<\/p>\n\n\n\n

                            Kas ir lab\u0101k: LDL-C vai ApoB?<\/strong>
                            ApoB<\/strong> bie\u017ei prec\u012bz\u0101k atspogu\u013co aterog\u0113no da\u013ci\u0146u skaits<\/strong>. Ja iesp\u0113jams, izmantojiet Abi<\/strong>.<\/p>\n\n\n\n

                            Vai Lp(a) var \u201esamazin\u0101t\u201c ar uztura bag\u0101tin\u0101t\u0101jiem?<\/strong>
                            Uzticami, pla\u0161i ieteikti uztura bag\u0101tin\u0101t\u0101ji nav pieejams<\/strong>. Da\u017eas vielas tiek apspriestas, bet kl\u012bniskie ieguvumi Nav pier\u0101d\u012bts<\/strong>. Lp(a) - galvenok\u0101rt \u0123en\u0113tiskais<\/strong> faktors; strat\u0113\u0123ija - agres\u012bv\u0101ka<\/strong> citu riska faktoru (ApoB, asinsspiediens, glik\u0113mija, dz\u012bvesveids) p\u0101rvald\u012bbu.<\/p>\n\n\n\n

                            Vai omega-3 ir piem\u0113rotas ikvienam?<\/strong>
                            Bie\u017ei vien j\u0101, bet piel\u0101gojiet devu un formu, lai Uzturs<\/strong>, triglicer\u012bdi<\/strong> st\u0101voklis un \u0101rsts<\/strong> ieteikumus (\u012bpa\u0161i, ja lietojat asins \u0161\u0137\u012bdin\u0101t\u0101jus).<\/p>\n\n\n\n

                            Cik bie\u017ei man j\u0101veic p\u0101rbaudes?<\/strong>
                            P\u0113c izmai\u0146\u0101m (di\u0113ta, uztura bag\u0101tin\u0101t\u0101ji, medikamenti) - 8-12 ned\u0113\u013cas<\/strong>, turpm\u0101k tekst\u0101 - ik p\u0113c 6-12 m\u0113ne\u0161iem.<\/strong> balst\u012bta uz risku.<\/p>\n\n\n\n

                            Vai CAC ir dom\u0101ts ikvienam?<\/strong>
                            N\u0113. Visbie\u017e\u0101k tiek \u0146emts v\u0113r\u0101, ja risks Vid\u0113ja<\/strong> un j\u0101pie\u0146em l\u0113mums par z\u0101les<\/strong>. Tas nav univers\u0101ls tests.<\/p>\n\n\n\n

                            Kopsavilkums:<\/strong><\/h4>\n\n\n\n

                            Ilgm\u016b\u017e\u012bba sirds vesel\u012bbai neat\u0146emama sast\u0101vda\u013ca<\/strong> no divas asis<\/strong>: ApoB\/LDL<\/strong> samazin\u0101\u0161ana un uzliesmojo\u0161s tonuss<\/strong> p\u0101rvald\u012bba. Di\u0113ta (Vidusj\u016bras re\u0123iona), fizisk\u0101s aktivit\u0101tes, miegs, stresa vad\u012bba, svara optimiz\u0101cija un p\u0101rdom\u0101ti, kvalitat\u012bvi uztura bag\u0101tin\u0101t\u0101ji (EPA\/DHA, \u0161\u0137\u012bsto\u0161\u0101s \u0161\u0137iedrvielas, augu ster\u012bni\/stanoli, bergamotes polifenoli, kurkum\u012bns, Q10). ilgtsp\u0113j\u012bgs pamats<\/strong>. Kad jums tas ir nepiecie\u0161ams - aptiekas<\/strong> l\u0113mumus ar savu \u0101rstu un konsekventa uzraudz\u012bba<\/strong>. \u201eSliktais holester\u012bns\u201c - svar\u012bgs, bet viens r\u0101d\u012bt\u0101js<\/strong> vairs neatspogu\u013co visu st\u0101stu.<\/p>","protected":false},"excerpt":{"rendered":"

                            Ilgaam\u017ei\u0161kumas ir \u0161irdies sveikata: kod\u0117l vien blogojo cholesterolio nepakanka \u0160irdies ir kraujagysli\u0173 lig\u0173 rizik\u0105 lemia ne vien LDL skai\u010dius. Svarbu matyti vis\u0105 vaizd\u0105: kiek aterogenini\u0173 daleli\u0173 cirkuliuoja kraujyje (ApoB), koks yra l\u0117tinis u\u017edegiminis fonas (hsCRP) ir kokia endotelio \u2013 kraujagysli\u0173 vidinio sluoksnio \u2013 b\u016bkl\u0117. Jei daleli\u0173 daug ir kartu vyrauja u\u017edegimas, plok\u0161tel\u0117s linkusios b\u016bti aktyvesn\u0117s […]<\/p>\n","protected":false},"author":38,"featured_media":41212,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[310],"tags":[],"class_list":["post-41207","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ilgaamziskumo-gidas"],"acf":[],"_links":{"self":[{"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/posts\/41207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/comments?post=41207"}],"version-history":[{"count":0,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/posts\/41207\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/media\/41212"}],"wp:attachment":[{"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/media?parent=41207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/categories?post=41207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/tags?post=41207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}